This presentation will help inform listeners about the multidisciplinary care of patients with lymphoma, the use of contemporary treatment fields (e.g. INRT, ISRT), appropriate use of technology (i.e. IMRT, VMAT, deep inspiration breath hold, proton beam therapy), new targeted therapies, immunotherapy, and treatment guidelines. The goal is to provide participants with updates on current clinical and translational initiatives in hematologic malignancies that are relevant to daily clinical practice. Additionally, attendees will be updated on the appropriate integration of these advancements in their daily practice, including indication, patient selection, and combinations of different therapeutic modalities, and management of common toxicities.
The meeting is designed to meet the interests of radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Discuss the current guideline-based clinical practice in hematologic malignancies.
- Discuss PET/CT response adaptive radiotherapy protocols for Hodgkin lymphoma and non-Hodgkin lymphoma.
- Explain the application of involved-site radiotherapy (ISRT) for all disease sites – including Hodgkin lymphoma, and non-Hodgkin lymphoma.
- Discuss the importance of multidisciplinary care in hematologic malignancies and how to best apply it for optimal outcomes.
- Describe key advances in immunotherapy and targeted therapy in hematologic malignancies.
- Discuss recent advances in new technology integration (i.e. IMRT, VMAT, deep inspiration breath hold, proton therapy) and how and when to integrate them.
- Discuss late effect of radiotherapy and how to best utilize current knowledge for decision-making.
Bradford S. Hoppe, MD, MPH, and is employed by the Mayo Clinic, Jacksonville. He received funding from Merck and PAU. He serves in leadership positions with NRG and PTCOG.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.